Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Artemis 2 astronaut Victor Glover delivers inspiring Easter message on the way to the moon (video) - 2The most effective method to Keep up with Proficient Handshakes in a Computerized World
- 3How Mars 'punches above its weight' to influence Earth's climate
- 4Strength training is crucial after menopause. How to make the most of your workouts
- 5NASA says Maven spacecraft that was orbiting Mars has gone silent
- The most effective method to Plan an Incineration Administration: A Bit by bit Guide.
- What is IDF's view on pontential long-term occupation of southern Lebanon?
- German police 'cleared path for fascists with batons,' protesters say
- 6 Robot Vacuum Cleaners for Easy Home Cleaning
- Make your choice for the music application with the most amicable connection point!
- I work with companies to confront addiction in the workplace. The hidden crisis is costing corporate America millions.
- The Best Portable Applications for Emotional wellness and Prosperity
- In blow to Lula, Brazil Congress revives controversial environmental bill
- Astrophotographer captures rare footage of the Hubble Telescope crossing the sun (video)
